top of page
Search

Insulet: New product cycle

  • Writer: Abacus Research
    Abacus Research
  • Sep 17, 2024
  • 1 min read

Insulet is a ~$17b market cap insulin pump leader.

  1. The primary bet is the Omnipod 5 driven product cycle:The approvals / product launches are mostly done, it is now just a question of execution and market demand.

  2. Insulet’s has seen significant devaluation on the back of GLP-1s.

    • The secondary bet is that the ‘negative’ impact of GLP-1s is negligible over the next decade. If this is proven, the multiple should expand

    • Note that GLP1s have no impact on type 1 diabetes, insulet’s core customer.


In our upside scenario we see a path to $3.6bn in 2027 revenues (2023-27 CAGR of 21%) and an EPS of $6.50 (25% CAGR), with EPS ~10% above consensus.


Potential Upside:     $320 (+37%)

Sensible Downside: $195(-16%)


 
 
 

Recent Posts

See All
SEDG, ENPH, NVTS: Plays on 800V

Everybody knows about the 800V conversion that is coming. NVDA etc have released the specs. There are many parts to that ecosystem change. Most of them are not ‘free options’ whereas SEDG and ENPH mos

 
 
 
Axon:

Axon is shifting from selling individual tools to providing an interconnected ecosystem. Hardware like TASERs and cameras now act as "data generators" that feed directly into high-margin software modu

 
 
 
C.H. Robinson

CHRW has been going through significant change, They are retaking market share. The new CEO has transformed the company by bringing in a lean / AI, that has helped CHRW to grow earnings despite strugg

 
 
 

Comments

bottom of page